FindTrial
Sign In

The effect of intracoronary nicorandil in improving coronary blood flow during primary angioplasty

The efficacy of intracoronary Nicorandil prior to stenting in prevention of no-reflow/ slow-reflow phenomenon during primary angioplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/015937
Enrollment
100
Registered
2018-10-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I219- Acute myocardial infarction, unspecified Health Condition 2: I219- Acute myocardial infarction, unspecified

Interventions

Intervention1: randomised control trial: Subjects in the Nicorandil Group will be then given 2 mg intracoronary nicorandil prior to stent implantation. In the Control Group, conventional primaryPCI wi

Sponsors

Dr Sreejith A G
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing primary PCI

Exclusion criteria

Exclusion criteria: patients with cardiogenic shock; severe liver, renal, or brain dysfunction; or other serious complications at the time of admission were excluded. Those who had taken nicorandil prior to admission w also excluded

Design outcomes

Primary

MeasureTime frame
improvement in TIMI flow gradeTimepoint: improvement in TIMI flow grade after balloon dilatation before stenting—

Secondary

MeasureTime frame
nilTimepoint: NA—

Countries

India

Contacts

Public ContactSreejith A G

kearala university of health sciences

vinayakumard@gmail.com9847015011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026